bullous drug eruption with features of Stevens-Johnson syndrome; bullous drug eruption with features of Stevens-Johnson syndrome; painful rash; blisters; persistent skin lesions; myalgia; fever; This literature-non-study case was reported in a literature article and describes the occurrence of DERMATITIS BULLOUS (bullous drug eruption with features of Stevens-Johnson syndrome), STEVENS-JOHNSON SYNDROME (bullous drug eruption with features of Stevens-Johnson syndrome), RASH (painful rash), BLISTER (blisters) and SKIN LESION (persistent skin lesions) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.   The patient's past medical history included Hypertension, Hyperlipidemia, Diabetes mellitus, Chronic kidney disease, Coronary artery disease and Hypothyroidism congenital. Family history included Myasthenia gravis (Patient's sibling, who died of complications of myasthenia gravis). Concurrent medical conditions included Obesity and Alcohol use. Concomitant products included AMLODIPINE, ACETYLSALICYLIC ACID (ASPIRIN 81), BRIMONIDINE, CLOPIDOGREL, FAMOTIDINE, FUROSEMIDE, GABAPENTIN, INSULIN ASPART, INSULIN GLARGINE, LEVOTHYROXINE, LISINOPRIL, METOPROLOL, PRAVASTATIN and TAMSULOSIN for an unknown indication.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DERMATITIS BULLOUS (bullous drug eruption with features of Stevens-Johnson syndrome) (seriousness criteria hospitalization prolonged and medically significant), STEVENS-JOHNSON SYNDROME (bullous drug eruption with features of Stevens-Johnson syndrome) (seriousness criteria hospitalization prolonged and medically significant), RASH (painful rash) (seriousness criterion hospitalization prolonged), BLISTER (blisters) (seriousness criterion hospitalization prolonged), SKIN LESION (persistent skin lesions) (seriousness criterion hospitalization prolonged), MYALGIA (myalgia) and PYREXIA (fever). The patient was hospitalized from sometime in 2021 to sometime in 2021 due to BLISTER, DERMATITIS BULLOUS, RASH, SKIN LESION and STEVENS-JOHNSON SYNDROME. The patient was treated with IBUPROFEN for Adverse event, at an unspecified dose and frequency; PREDNISONE (oral) for Adverse event, at an unspecified dose and frequency; MUPIROCIN for Adverse event, at an unspecified dose and frequency and Wound care (bullae were drained) for Dermatitis bullous. At the time of the report, DERMATITIS BULLOUS (bullous drug eruption with features of Stevens-Johnson syndrome), STEVENS-JOHNSON SYNDROME (bullous drug eruption with features of Stevens-Johnson syndrome), RASH (painful rash), BLISTER (blisters), SKIN LESION (persistent skin lesions), MYALGIA (myalgia) and PYREXIA (fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, Antibody test: positive (Positive) serum antibodies to bullous pemphigoid (BP), BP 180 and BP 230, were 8 and <2 respectively (within the normal limit with range <20). In 2021, Biopsy: abnormal (abnormal) The histopathology showed full-thickness epidermal necrosis and a very sparse lymphocytic inflammatory infiltrate.. In 2021, Blood creatine phosphokinase: high (High) 347 and an incidental findings of mild Acute Kidney Injury on Chronic Kidney Disease.. In 2021, Blood glucose: high (High) hyperglycemia. In 2021, Blood potassium: high (High) hyperkalemia. In 2021, Body mass index: 31.65 (High) high. In 2021, Physical examination: abnormal (abnormal) extensive areas of painful violaceous patches on his abdomen, buttocks and lower extremities, many of which developed into large flaccid bullae. Patient had no involvement in his mucous membranes, palms, soles, joints or targetoid lesions. Significant lower extremity muscle tenderness, stiffness with preserved strength. In 2021, SARS-CoV-2 test: negative (Negative) negative. In 2021, Transaminases: high (High) mild transaminitis. In 2021, Vital signs measurement: normal (normal) normal.     mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered DERMATITIS BULLOUS (bullous drug eruption with features of Stevens-Johnson syndrome), STEVENS-JOHNSON SYNDROME (bullous drug eruption with features of Stevens-Johnson syndrome), RASH (painful rash), BLISTER (blisters), SKIN LESION (persistent skin lesions), MYALGIA (myalgia) and PYREXIA (fever) to be possibly related.    Patient has no known drug or food allergy or rheumatological disease. Patient denied smoking or recreational drug use.  This is a 66-year-old male patient who experienced dermatitis bullous and Stevens-Jonson syndrome among others on an unspecified date after mRNA1273 administration. Very limited information regarding this event has been provided at this time. Date of vaccination, date of event onset  and discharge summary is required for further assessment.   Most recent FOLLOW-UP information incorporated above includes: On 26-Jul-2021: Follow up received by safety on 28-Jul-2021 included a nonsignificant ICSR abstract.; Sender's Comments: This is a 66-year-old male patient who experienced dermatitis bullous and Stevens-Jonson syndrome among others on an unspecified date after mRNA1273 administration. Very limited information regarding this event has been provided at this time. Date of vaccination, date of event onset  and discharge summary is required for further assessment.